Among them, erythropoietin (EPO) may stimulate EMT in RCC via the PI3K/Akt/mTOR pathway (36) in agreement with the observations that the mTOR inhibitor Everolimus was able to slow down RCC tumor growth and to reverse EMT phenotype in a mouse xenograft model (37). This evidence concerns the gene MTOR and renal cell carcinoma.